Cabozantinib
Inquiry
| Post Date: | Jan 09,2018 |
| Expiry Date: | Jul 08,2018 |
| Detailed Description: |
Cas No. :849217-68-1
Quantity: mass in stockKilograms Specs:white powder Price:negotiable USD Kilograms Payment Method: T/T, Western Union,Moneygram and Bitcoin. Description Cabozantinib, marketed under the trade name Cabometyx among others, is a small molecule inhibitor of the tyrosine kinases c-Met and VEGFR2, and has been shown to reduce tumor growth, metastasis, and angiogenesis. It was discovered and developed by Exelixis Inc. Cabozantinib was granted orphan drug status by the U.S. Food and Drug Administration (FDA) in January 2011.Cabozantinib is approved by the U.S. FDA for medullary thyroid cancer. and advanced renal cell carcinoma in people who have received prior anti-angiogenic therapy. It is currently undergoing clinical trials for the treatment of prostate, bladder, ovarian, brain, melanoma, breast, non-small cell lung, pancreatic, and hepatocellular cancers. Cabozantinib inhibits the activity of tyrosine kinases including MET, AXL, VEGF receptors, and RET. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, drug resistance, and maintenance of the tumor microenvironment. Function Cabozantinib (marketed under the tradename Cometriq, formerly known as XL184) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM. XL-184 also displays potent activity against Met, Ret, Kit, FLT1, FLT3, FLT4, Tie2, and AXL. XL184 at low concentration(0.1-0.5 μM) is sufficient to induce marked inhibition of constitutive and inducible Met phosphorylation and its resultant downstream signaling in MPNST cells, and inhibit HGF-induced MPNST cell migration and invasion |
| CAS Registry Number: | 849217-68-1 |
| Synonyms: | ;N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;XL184;BMS-907351;Cabozantinib;N-[4-[(6,7-Dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide;1,1-cyclopropanedicarboxamide, n'-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n-(4-fluorophenyl)-; |
| Molecular Formula: | C28H24FN3O5 |
| Molecular Structure: | ![849217-68-1 1,1-Cyclopropanedicarboxamide,N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)-](https://images.chemnet.com/suppliers/chembase/cas243/849217-68-1.gif)
|
| Company: | Hengyang Desen Biotechnology Co., Ltd. [ China ] |
| Contact: | ava |
| Tel: | 86-18908446905 |
| Fax: | |
| Email: | ava@ycgmp.com |
-
Disclaimer statement:The information and data included above have been realized by the enterprises and compiled by the staff, and are subject to change without notice to you. The Chemnet makes no warranties or representations whatsoever regarding the facticity, accuracy and validity of such information and data. In order to ensure your interest, we suggest you chose the products posted by our gold suppliers or VIP members.
